Consequently, patients who experience chemotherapy-induced ovarian failure develop rapid and highly significant decreases in BMD that are detectable within 6 months of starting chemotherapy [ 58 ].
← all excerpts
A Representative Clinical Course of Progression, with Molecular Insights, of Hormone Receptor-Positive, HER2-Negative Bone Metastatic Breast Cancer.
1
—
—